Zota Health Care LImited (ZOTA:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Zota Health Care LImited stock forecast from 0 analysts, the average analyst target price for Zota Health Care LImited is not available over the next 12 months. Zota Health Care LImited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Zota Health Care LImited is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Zota Health Care LImited’s stock price was INR 486.40. Zota Health Care LImited’s stock price has changed by +0.03% over the past week, +1.70% over the past month and +74.31% over the last year.
No recent analyst target price found for Zota Health Care LImited
No recent average analyst rating found for Zota Health Care LImited
Company Overview Zota Health Care LImited
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers generic drugs, over-the-counter products, ayurvedic products, and nutraceutical products. The company provides various medicines for chronic illnesses, including diabetes, heart conditions, and thyroid disorders. It operates its retail stores under the DAVAINDIA name. The company also exports its products to approximately 30 countries. Zota Health Care Limited was founded in 1995 and is headquartered in Surat, India. Read Less
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers generic drugs, over-the-counter products, ayurvedic products, and nutraceutical products. The company provides various medicines for chronic illnesses, inc...Read More
Frequently Asked Questions About Zota Health Care LImited (ZOTA:NSE) Stock
Stock Target Advisor's fundamental analysis for Zota Health Care LImited's stock is Slightly Bearish.
ZOTA:NSE stock's dividend yield is 0.20%.
Our analysis grades ZOTA:NSE stock's dividend yield at D-. This means that ZOTA:NSE stock's dividend yield is above 60% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this ZOTA:NSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on ZOTA:NSE's stock to indicate what its average analyst target is.
ZOTA:NSE stock's Price/Earning ratio is 158.70.
Our analysis grades ZOTA:NSE stock's Price / Earning ratio at F. This means that ZOTA:NSE stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this ZOTA:NSE may be a overvalued for its sector.
The last closing price of ZOTA:NSE's stock was INR 486.40.
The most recent market capitalization for ZOTA:NSE is INR 12.61B.
Unfortunately we do not have enough analyst data on ZOTA:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Zota Health Care LImited's stock.
As per our most recent records Zota Health Care LImited has 338 Employees.
Zota Health Care LImited's registered address is Zota House, Surat, India, 395002.
You can get more information about it from Zota Health Care LImited's website at https://www.zotahealthcare.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ZOTA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
